Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialEdward S. Kim, Jean‐Yves Douillard, Yan Sun et al.|The Lancet|2008Cited by 1.2k
Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung CancerJoachim von Pawel, Markus F. Renschler, Robert M. Jotte et al.|Journal of Clinical Oncology|2014Cited by 344
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung CancerMark A. Socinski, Howard West|JAMA Oncology|2023Cited by 182
Cardiac synovial sarcoma with translocation (X; 18) associated with asbestos exposureCielette M. Karn, John E. Craighead, Mark A. Socinski et al.|Cancer|1994Cited by 64
Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM)Silvia Novello, Giorgio V. Scagliotti, Anna K. Nowak et al.|Annals of Oncology|2017Cited by 0